ClinicalTrials.gg
RecruitingNCT06195800BIO-MSUpdated Oct 7, 2026

Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation

An observational study in Multiple Sclerosis, Relapsing-Remitting, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Sheffield Teaching Hospitals NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Oct 7, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
15
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom — 3 open to participants now, 8 under way, 3 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · United Kingdom.

Started
2023
the only one that year
Observational
9 of 60
2 open now
Registered
57th of 60
by date

Among the 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom, this one is the only one that started in 2023, is one of 9 observational ones, and was the 57th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

3 of the 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United Kingdom, or all of them as a file.
02

Study summary

The underlying disease mechanisms which occur in patients with immune mediation neurological diseases, such as Multiple Sclerosis (MS), are incompletely understood. For such patients, autologous haematopoietic stem cell transplantation (aHSCT) has been increasingly used as a highly successful one-off treatment for some patients. This treatment aims to delete the faulty immune system with a course of chemotherapy and then 'reboot' the immune system using a patients' own stem cells (a cell with the unique ability of being a building block to create many different cells in the body) to stop further damage. Over the last 20 years more than 1800 patients with MS have been treated in Europe with high levels of success. It may be more successful than disease modifying treatment but unfortunately, a small portion of people do not respond to this treatment optimally and continue to accumulate disability. There is a risk of side effects, restricted largely to the time of treatment, which necessitates the need to ensure appropriate patients are treated. Whilst aHSCT is a very effective therapy, it is still in its early phase of development, is not in widespread use, and there is incomplete knowledge regarding how it works and importantly, why it does not work in some patients, and how to monitor response to treatment.

Unfortunately, there is no way of detecting which patients will, and will not, benefit from the different treatments available or a way of monitoring the immune system to ensure further treatment is provided before irreversible damage occurs.

This study will investigate the immune system which is found in the fluid surrounding the brain and spinal cord, blood and stool of patients undergoing aHSCT and compare it to those receiving disease modifying treatment. This study will therefore further the understanding of biomarkers of aHSCT to develop an awareness of how it can be refined, may improve monitoring of patients following treatment and permit the development of markers which can predict potential treatment success or failure before patients are exposed to the risks.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • multiple sclerosis
  • aHSCT
  • Autologous haematopoetic stem cell transplantation
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Outpatients who are attending the Sheffield (UK) transplant clinic for neurological disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of a immune mediated neurological disease according to disease specific criteria (active treatment arm) or diagnosis of relapsing remitting multiple sclerosis (control arm).
  2. Treatment with autologous haematopoetic stem cell transplantation (active treatment arm) or high efficacy disease modifying treatment (control arm).
  3. Willing to provide biological samples for analysis and undergo clinical assessments for the duration of follow up.
  4. Able to understand English and provide .

Exclusion criteria

Exclusion Criteria:

1. Inability to provide .

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients treated with aHSCT

    Patients with aggressive disease treated with autologous haematopoetic stem cell transplantation.

  • Patients treated with disease modifying treatment

    Patients with aggressive disease treated with high efficacy disease modifying treatment

06

What researchers measure

Primary outcomes

  1. Quantitatively and qualitatively characterise the immune profile of the stem cells, blood, cerebrospinal fluid (CSF) and the microbiome pre and post treatment.

    Phenotype profiling of stem cells, cells in blood and CSF using multi-parameter flow cytometry. Profile the gut microbiome using 16S rRNA sequencing and flow cytometric analysis.

    Time frame: 24 months

  2. Perform single cell RNA sequencing (scRNA-Seq) on paired CSF and blood pre and post treatment.

    Profiling of T cell receptor and B cell receptor repertoire diversity and clonality

    Time frame: 24 months

Secondary outcomes

  1. Characterisation of the regeneration of mucosal cell immunity and the reconstitution of pathogen specific immunity following aHSCT by scRNA-Seq on nasopharyngeal swabs and mucosal strips.

    Assess immune response in treated patients post vaccination.

    Time frame: 24 months

  2. Evaluate immunological disease response and the duration of response to aHSCT according to expanded disability status scale score (EDSS)

    EDSS to be observed longitudinally following treatment.

    Time frame: 24 months

  3. Evaluate immunological disease response and the duration of response to aHSCT according to low contrast visual acuity (LCLA)

    LCLA to be observed longitudinally following treatment.

    Time frame: 24 months

  4. Evaluate immunological disease response and the duration of response to aHSCT according to multiple sclerosis functional composite score (MSFC)

    MSFC to be observed longitudinally following treatment.

    Time frame: 24 months

  5. Evaluate immunological disease response and the duration of response to aHSCT according to short form 36 (SF-36)

    SF-36 to be observed longitudinally following treatment.

    Time frame: 24 months

  6. Evaluate immunological disease response and the duration of response to aHSCT according to symbol digit modality test (SDMT)

    SDMT to be observed longitudinally following treatment.

    Time frame: 24 months

  7. Evaluate immunological disease response and the duration of response to aHSCT according to Karnofsky performance status

    Karnofsky performance status to be observed longitudinally following treatment.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2027, 51 months after the start.

Of 42 non-industry observational studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 56. This study's planned 51 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 22 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Aug 2026 → Nov 2027 and completion Aug 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Jan 8, 2024
StartActual
Aug 9, 2023
Primary completionEst.
Nov 30, 2027was Aug 2026
CompletionEst.
Nov 30, 2027was Aug 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 9, 2026→Nov 30, 2027
Oct 7, 2026
Study completion
Aug 9, 2026→Nov 30, 2027
Oct 7, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Sheffield Teaching Hospitals NHS Foundation Trust · Sheffield, United KingdomContact •••9027→none listed
Oct 7, 2026
Title
Biomarkers of aHSCT→Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Primary completion Aug 9, 2026→Nov 30, 2027
    Study completion Aug 9, 2026→Nov 30, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Sheffield Teaching Hospitals NHS Foundation Trust · Sheffield, United KingdomContact •••9027→none listed
    Title Biomarkers of aHSCT→Identifying Immune Biomarkers of Disease and Disease Control in Autoimmune Neurological Disease Using Autologous Haematopoietic Stem Cell Transplantation
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06195800
Collaborators
Sheffield Hospitals Charity, Nottingham Trent University, University of Sheffield
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Aug 9, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Gavin Brittain, MBBS, MRCP
Contact
gavin.brittain@sheffield.ac.uk
+44114 271 1900
Gavin Brittain, MBBS, MRCP
principal investigator · Sheffield Teaching Hospitals NHS Foundation Trust and The University of Sheffield

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion